PRECLINICAL: Marton et al. 2019 — Ibogaine Modifies GDNF/BDNF Expression in Rat Dopaminergic Circuits

Definition box

Definition: LABEL: PRECLINICAL (animal / not human clinical proof). Marton S. et al. (2019) *Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits*, *Frontiers in Pharmacology* 10:193 (doi: 10.3389/fphar.2019.00193; PMID 30890941; PMC PMC6411846). Rats received acute intraperitoneal ibogaine 20 or 40 mg/kg (or vehicle); GDNF, BDNF, and NGF transcript/protein readouts were assayed in VTA, PFC, NAcc, and SN at 3 h and 24 h. At 24 h, 40 mg/kg selectively upregulated GDNF in VTA and SN (protein increase detected in VTA); both doses increased BDNF mRNA in NAcc/SN/PFC (VTA BDNF mRNA mainly at 40 mg/kg); proBDNF rose in NAcc; mature BDNF protein did not show significant regional increases in the assayed areas. This is mechanistic animal neuroscience—not human RCT evidence, not proof of clinical “brain resetting,” and not psychoactive IV ibogaine infusion efficacy in people. Clinical cardiac risk (QTc) remains relevant to any human use discussion even though this paper is not a cardiology study. Ibogaine is U.S. Schedule I / not FDA-approved. No cure claims.

Quotable answer (54 words)

Marton and colleagues’ 2019 Frontiers in Pharmacology rat study found dose- and region-dependent increases in GDNF and BDNF-related expression after intraperitoneal ibogaine—especially GDNF in the VTA at 40 mg/kg. Preclinical neurotrophic changes are not human clinical proof and not psychoactive IV ibogaine infusion evidence. Label animal data clearly.

Why this spoke exists

Marketing often leaps from “GDNF in the VTA” to “ibogaine rewires your brain / cures addiction.” YMYL response: name the paper, keep the PRECLINICAL label loud, and refuse human IV proof inflation. Soft CTA still points humans to screening—not to DIY animal-dose math: /safety-and-screening → /apply. Related preclinical spokes: /blog/belgers-2016-ibogaine-animal-meta-analysis, /blog/cameron-2020-tabernanthalog, /blog/ibogaine-18-mc-analog-preclinical.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Marton S. et al. *Front Pharmacol*. 2019;10:193. doi 10.3389/fphar.2019.00193. PMID 30890941 | | Species / route | Adult rats; i.p. ibogaine 20 or 40 mg/kg | | Regions | VTA, PFC, NAcc, SN | | Readouts | GDNF / BDNF / NGF mRNA; selected protein (GDNF, BDNF, proBDNF) | | Timepoints | 3 h and 24 h post-dose | | Headline mechanistic signal | 24 h site- and dose-dependent neurotrophic transcript changes; VTA GDNF protein ↑ at 40 mg/kg | | What it is not | Human trial; IV psychoactive brand study; behavioral addiction cure proof in this paper alone; cardiac safety study |

Key findings (plain language, no hype)

• Neurotrophic factor gene expression can rise a day after ibogaine in addiction-relevant circuits—in rats.
• GDNF in VTA at the higher dose aligns with earlier hypotheses linking GDNF to reduced alcohol self-administration in other rodent work (cited by authors)—still animal-to-animal inference.
• BDNF mRNA ≠ mature BDNF protein everywhere: transcript bumps did not automatically equal mature protein bumps in assayed regions; proBDNF changes add interpretive complexity.
• Dose matters: 20 vs 40 mg/kg were not interchangeable.
• Authors call for more research on whether these molecular changes explain anti-drug-seeking behavior.

Honest reading: Plausible plasticity mechanism class; zero permission to claim human clinical neuroplasticity proof or IV brand efficacy.

Translation rules (YMYL)

| Leap | Status | |------|--------| | Rat GDNF → “clinically proven brain healing” | Not allowed | | Rat i.p. → human oral clinic dose equivalence | Not established here | | Rat data → psychoactive IV ibogaine proof | False | | Mechanism hypothesis for future trials | Reasonable if labeled preclinical |

Cardiac reminder (even on a preclinical page)

Human readers arrive via addiction/PTSD searches. Mechanism hope does not cancel QTc/fatality literacy (/blog/alper-herg-ibogaine-cardiac-mechanism, /blog/knuijver-2021-ibogaine-qtc-safety, /safety-and-screening). Cerebellar toxicity history in high-dose animals is a separate preclinical safety lane (/blog/ibogaine-purkinje-cerebellar-toxicity).

Route honesty & entity clarity

Intraperitoneal rodent dosing ≠ physician-supervised psychoactive IV ibogaine infusion in humans. Oral clinic literature ≠ this assay. Do not paste VTA GDNF figures into IV brand ads.

Limits

| Limit | Why it matters | |-------|----------------| | Animal only | Species translation uncertain | | Acute single-dose design | Not chronic human dosing ecology | | Molecular endpoints | Behavior not the primary readout in this paper | | i.p. route | PK differs from oral/IV human use | | No human IV arm | Brand entity untouched |

How marketers misuse neurotrophic language

Phrases like “ibogaine releases GDNF,” “restores dopamine neurons,” or “opens critical periods like psychedelics” sometimes cite Marton 2019 or related reviews without saying rat, i.p., or hypothesis. Responsible SEO names the species, dose, and endpoint class every time. Psychoplastogen analogies to ketamine/psilocybin dendritic work are research-frame comparisons—not interchangeable product claims for ibogaineinfusion.com.

Aftercare still beats mechanism slogans

Even if future human studies confirmed neurotrophic shifts, recovery would still need sleep, contingency management, trauma therapy, and relapse planning (/blog/ibogaine-aftercare-integration). Molecules do not replace psychosocial care.

Relationship to classic GDNF alcohol work

Earlier rodent alcohol self-administration studies (often cited alongside Marton) proposed VTA GDNF as a mediator of ibogaine’s anti-addictive persistence. Marton 2019 supplies region-resolved expression mapping that makes that hypothesis more anatomically specific—without converting it into a human outcomes trial. Keep the citation chain honest: animal behavior papers ≠ human IV brand RCTs.

NGF signal

NGF mRNA rose broadly after 40 mg/kg in Marton’s maps. That widens the neurotrophic story beyond GDNF/BDNF slogans but also increases the temptation to over-claim “growth factor therapy.” Resist.

What this page is for in the content cluster

Use Marton 2019 when a reader asks “does ibogaine grow GDNF?” Answer: in rats, regionally, at certain doses, on mRNA/protein assays—yes, with caveats. Then pivot to human evidence tiers (observational OUD/PTSD papers) and cardiac screening. Mechanism spokes should reduce magical thinking, not feed it.

Even careful mechanism literacy does not change Schedule I status or the need for ECG-capable supervision in any human pathway discussed on this site.

Soft CTA

Curious about mechanisms? Still start with human safety screening if considering treatment pathways: /safety-and-screening → /apply.

FAQ

Is this a human study? No. **PRECLINICAL** rat study.

DOI / PMID? doi **10.3389/fphar.2019.00193**; PMID **30890941**.

Does GDNF prove ibogaine cures addiction? No. Mechanistic animal signal only.

Was psychoactive IV ibogaine tested? No.

Can I scale 40 mg/kg rat i.p. to myself? No. Dangerous and unsupported.

Why mention cardiac risk on a rat page? Because human readers convert mechanism pages into treatment decisions; QTc risk remains clinically relevant.

Is ibogaine FDA-approved? No. Schedule I.

Where should screening start? /safety-and-screening → /apply.

Sources (selected)

1. Marton S. et al. *Front Pharmacol*. 2019. doi: 10.3389/fphar.2019.00193. PMID: 30890941.
2. Belgers M. et al. *Transl Psychiatry*. 2016. doi: 10.1038/tp.2016.71 (animal meta-analysis).
3. Cameron L.P. et al. *Nature*. 2021. doi: 10.1038/s41586-020-3008-z (analogue preclinical).
4. Alper K. et al. *Cardiovasc Toxicol*. 2016. doi: 10.1007/s12012-015-9311-5.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical advice. This page summarizes preclinical animal data and is not evidence of human efficacy or safety for any ibogaine route. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some human contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Marton 2019 is preclinical—not a cure claim and not psychoactive IV ibogaine infusion proof.